-
The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions
Sunday, November 8, 2020 - 1:47pm | 4415Read More...Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE) shares came...
-
FDA Approves First Ebola Vaccine
Friday, December 20, 2019 - 3:45am | 252Read More...American pharmaceutical company Merck & Co., Inc. (NYSE: MRK) received FDA approval for its Ebola vaccine Ervebo on Thursday, according to Reuters. What Happened The FDA said had approved Merck’s Ebola vaccine, Ervebo, making it the first FDA-approved vaccine against the lethal virus...
-
No Legwork Mondays – Merck And Vioxx
Monday, April 14, 2014 - 9:45am | 499Read More...One of the clichés about the 21st century is that seniors are living longer, thanks to health care providers and drug makers. And like many clichés this saying has its roots in reality. Unfortunately, sometimes these purveyors of health have failed miserably. In the case of...
-
Deutsche Bank Comments On Merck And Roche Collaboration
Thursday, May 19, 2011 - 7:55am | 93Read More...According to Deutsche Bank, Merck & Co (NYSE: MRK) announced this week that they had established a broad HCV alliance, across all major facets of the therapeutic area, including marketing, diagnostics, and R&D. Deutsche Bank said that as part of the agreement, Roche will co-promote MRK's...
-
Piper Jaffray Discontinues Coverage On ISPH
Tuesday, May 17, 2011 - 7:31am | 106Read More...Piper Jaffray is discontinuing its coverage on Inspire Pharmaceuticals (NASDAQ: ISPH) as the company has been fully acquired by Merck & Co. (NYSE: MRK). Piper Jaffray most recently rated the stock at Neutral and held a $5 price target on the stock. Says Piper Jaffray, in the report, “Investors...
-
Goldman Sachs Reports on Merck & Co (MRK)
Monday, May 16, 2011 - 8:21am | 128Read More...In a report released yesterday by Goldman Sachs, the firm commented on Merck & Co. (NYSE: MRK). In the report, Goldman Sachs was mixed in its assessment. Goldman Sachs writes, “FDA granted MRK's Victrelis a limited label excluding null responders, which represents approximately 30% of...
-
J.P. Morgan Calls Merck & Co's Hep C Treatment A "Modest Positive"
Monday, May 16, 2011 - 7:37am | 86Read More...According to J.P. Morgan, Merck & Co (NYSE: MRK) got FDA approval for the Victrelis (boceprevir) for Hepatitis C, both in treatment-naive and treatment-experienced patients, on Friday. J.P. Morgan said that, while it views Victrelis as a nice incremental product opportunity, it (and the...
-
Merck & Co. (MRK) Reports Schering Fueled Profit Jump
Tuesday, February 16, 2010 - 9:24am | 96Read More...Drug maker Merck & Co. Inc. (NYSE: MRK) reported that its 4th quarter earnings rose on the back of its $41 billion acquisition of Schering Plough. Merck & Co. reported net income of $6.49 billion, or $2.35 per share, compared with $1.64 billion, or 78 cents per share, during the same...
-
Merck & Co. (MRK) Agrees To Changes In Vioxx Settlement
Wednesday, February 10, 2010 - 4:10pm | 214Read More...Merck & Co. Inc. (NYSE: MRK) agreed to settle shareholder lawsuits related to its withdrawn Vioxx painkiller by paying $12.2 million in legal fees, appointing a Chief Medical Officer and promising to improve its drug safety procedures. Vioxx was withdrawn by Merck & Co. in 2004 after a...
